Safety and pharmacokinetic study of sacubitril/valsartan (LCZ696) and atorvastatin in healthy Chinese male subjects

Trial Profile

Safety and pharmacokinetic study of sacubitril/valsartan (LCZ696) and atorvastatin in healthy Chinese male subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Atorvastatin
  • Indications Essential hypertension; Heart failure; Hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Jun 2016 New trial record
    • 31 May 2016 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top